+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 80Years
All Genders
ID07096934

Evaluation of CYWC628 with Standard Care for Treating Refractory Diabetic Foot Ulcers Compared to Standard Care Alone

Led by FibroBiologics · Updated on 2026-08-26

120

Participants Needed

9

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a prospective, multicenter, randomized clinical trial to assess the safety, tolerability, and effectiveness of up to 12 weeks of treatment with standard of care SoC combined with either low- or high-dose CYWC628 compared to SoC alone in adults with diabetic foot ulcers DFU. The trial focuses on participants with refractory DFU and evaluates wound healing and safety outcomes during and after treatment. Participants begin with a screening period including wound debridement, dressing with SoC, and offloading. If infection is present, it is treated until under control. Eligible participants whose wounds do not improve by at least 30% after two weeks are randomized into three groups SoC plus low-dose CYWC628, SoC plus high-dose CYWC628, or SoC alone. Treatments are applied once weekly for up to 12 weeks. Participants whose wounds heal enter follow-up visits, while those with unhealed wounds may have additional safety follow-up or enter a second treatment period depending on initial assignment. During the study, participants attend weekly visits for assessments including wound measurement using an electronic imaging device, ankle brachial index ABI testing, vital signs, and laboratory tests. Safety and adverse events are monitored closely, including an early safety review after the first two weeks of treatment. Follow-up visits continue after healing to assess recurrence, with the study lasting up to six months post-treatment. Participants who do not heal within 12 weeks may receive additional treatment or return to their usual care under physician guidance.

CONDITIONS

Brief Title

Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care

Research Team

H

Hamid Khoja Chief Scientific Officer, Ph.D.

P

Pete O'Heeron Chief Executive Officer, MBA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here